Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demons | ABUS Message Board Posts

Arbutus Biopharma

  ABUS website

ABUS   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  34809 of 34823  at  5/20/2020 11:30:08 PM  by

liuyiiv


 In response to msg 34806 by  stencil
view thread

Re: Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg

This early Ph1 data also validates Arbutus/Genevant GalNAc RNAi platform. It is as good and safe as competitors'. Look at the market cap of $DRNA and $ARWR. Both have only tech, no product.
 
When Genevant comes out from behind the curtain with "2~3 clinical programs by 2020", let us rejoice!


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 211
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...